3 results
6-K
EX-99.1
IFRX
InflaRx N.V.
8 Sep 22
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
8:00am
for 28-day
mortality (all Cox regression
models are age adjusted)
p-value
Hazard ratio (95% CI)
or risk difference for
logistic regression
Patient
6-K
EX-99.1
IFRX
InflaRx N.V.
31 Mar 22
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
4:51pm
Western European countries (n=209) showed a relative reduction in 28-day all-cause mortality of 43% (vilobelimab 21.2% versus placebo 37.2%, hazard
- Prev
- 1
- Next